MDSpire - Summary
Feature

Diagnostics Explores the Fragmentome

An AI-augmented blood test detects early liver fibrosis and other diseases

  • March 30, 2026

  • 5 min

Share

AI-based liquid biopsy tests using genome-wide cell-free DNA (cfDNA) fragmentation patterns show promise in detecting early liver fibrosis and cirrhosis, potentially revealing broader chronic disease indicators. Researchers Victor Velculescu and Akshaya Annapragada from Johns Hopkins Kimmel Cancer Center explain that cfDNA reflects the health of cells and can be assessed via low-cost blood tests. This innovative method can enhance early detection of liver diseases and has potential applications for other chronic conditions, highlighting the need for further validation.

Original Source(s)

Diagnostics Explores the Fragmentome

  • March 30, 2026

Related Content

AI As Collaborator in Cancer Research and in Clinical Care

Last October, the Cancer AI Alliance (CAIA) announced the launch of its collaborative artificial intelligence (AI) platform powered by federated learning to train AI models with millions of de-identif...

Metabolic Subtypes of Nasopharyngeal Carcinoma and Response to Treatment

In a Chinese study reported in the Journal of Clinical Oncology, Huang et al developed a classification for metabolic subtypes of nasopharyngeal carcinoma that may help identify patients benefiting mo...

The Diagnostic Impact of Color Vision

Study suggests reduced survival in bladder cancer patients with color vision deficiency

  • March 30, 2026

  • 2 min